Effects of risedronate on osteoarthritis of the knee

Yonsei Medical Journal

Volumn 51, Issue 2, 2010, Pages 164-170

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b   Matsumoto, Hideo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

Author keywords

Bisphosphonate; Knee; Osteoarthritis; Subchondral bone

Indexed keywords

COLLAGEN TYPE 2; CROSSLINKING TELOPEPTIDE OF TYPE II COLLAGEN; PLACEBO; RISEDRONIC ACID; UNCLASSIFIED DRUG;

CARTILAGE DEGENERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; KNEE OSTEOARTHRITIS; OSTEOLYSIS; PROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CARTILAGE; DIPHOSPHONATES; ETIDRONIC ACID; HUMANS; OSTEOARTHRITIS, KNEE;

EID: 77649220561     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.2.164     Document Type: Review

References (28)

1. Sowers M. Epidemiology of risk factors for osteoarthritis: systemic factors. Curr Opin Rheumatol 2001;13:447-51.
2. Kawaguchi H. Regulation of osteoarthritis development by Wntbeta-catenin signaling through the endochondral ossification process. J Bone Miner Res 2009;24:8-11.
3. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62.
4. Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003;15:413-8.
5. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
6. Muehleman C, Green J, Williams JM, Kuettner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002;10:226-33.
7. Bendele AM, Hulman JF. Spontaneous cartilage degeneration in guinea pigs. Arthritis Rheum 1988;31:561-5.
8. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005;7:R625-33.
9. Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
10. Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007;46:257-64.
11. Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008;16:660-6.
12. Bruyère O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008;9:165.
13. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
14. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
15. Centre for Evidence-Based Medicine. Oxford-Centre Evidence Based Medicine. Levels of Evidence and Grades of Recommendation. http://www.cebm.net/ levels-of-evidence.asp.
16. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002;46:3178-84.
17. Li B, Aspden RM. Mechanical and material properties of the subchondral bone plate from the femoral head of patients with osteoarthritis or osteoporosis. Ann Rheum Dis 1997;56:247-54.
18. Buckland-Wright JC, Macfarlane DG, Jasani MK, Lynch JA. Quantitative microfocal radiographic assessment of osteoarthritis of the knee from weight bearing tunnel and semiflexed standing views. J Rheumatol 1994;21:1734-41.
19. Wluka AE, Wang Y, Davis SR, Cicuttini FM. Tibial plateau size is related to grade of joint space narrowing and osteophytes in healthy women and in women with osteoarthritis. Ann Rheum Dis 2005;64:1033-7.
20. Jones G, Ding C, Scott F, Glisson M, Cicuttini F. Early radiographic osteoarthritis is associated with substantial changes in cartilage volume and tibial bone surface area in both males and females. Osteoarthritis Cartilage 2004;12:169-74.
21. Tissakht M, Ahmed AM, Chan KC. Calculated stress-shielding in the distal femur after total knee replacement corresponds to the reported location of bone loss. J Orthop Res 1996;14:778-85.
22. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002;46:3178-84.
23. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003;73:423-32.
24. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, Henriksen K, Qvist P, Christiansen C, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006;54:2441-51.
25. Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 2008;16:615-23.
26. Saag KG. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis 2008;67:1358-9.
27. Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT. The effect of alendronate on progression of spinal osteophytes and discspace narrowing. Ann Rheum Dis 2008;67:1427-30.
28. Bruyere O, Delferriere D, Roux C, Wark JD, Spector T, Devogelaer JP, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008;67:335-9.